• Karl Rotthier commences his tenure as Chief Executive Officer of Sterling Pharma Solutions
• Kevin Cook will retire at end of October 2025

Sterling Pharma Solutions announced the appointment of Karl Rotthier as Chief Executive Officer (CEO), effective 21 October, 2025. Karl Rotthier succeeds Kevin Cook, who has served as CEO since 2013 and has now taken the decision to retire. Kevin will work closely with Karl to ensure a smooth leadership transition until 31 October, 2025.

Chris Brinsmead CBE, Chair of the Sterling Board, commented: “We are delighted to welcome Karl to Sterling Pharma Solutions. Karl is a highly experienced CEO who has worked in both listed and private CDMO companies in Europe and globally. He has leadership experience working in fast-growing businesses that have expanded internationally and has a strong track record of driving commercial effectiveness and operational excellence.

“Our investors, GHO and Partners Group, would like to extend their gratitude to Kevin Cook for his dedication, vision, and leadership over his years at Sterling. He leaves behind a business that has greatly transformed from a single site in the UK to a multi-site global leader, having developed a culture of quality focused, customer-centric delivery, and a shared sense of purpose that will continue to shape Sterling’s future.”

Karl Rotthier said: “It is a privilege to join Sterling at an important time in the company’s growth and development. I have known Sterling for some years, having followed the growth of the business in the market. I am delighted to now have the opportunity to lead the business and leverage the market opportunities in Europe and the US, as well as to continue to invest in our antibody-drug conjugate business, ultimately to help bring critical therapies to patients worldwide.”